More than half of its gross sales ultimately went to payers as rebates, Sanofi says
In a new report, Sanofi is adding another data point to one of pharma’s go-to defenses regarding their pricing practices.
As much as 55% of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
